Jun Zhu

Hunan University — China

Medicine · Health Sciences

17h-index983citations236works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(52), Prostate Cancer Treatment and Research(46), Nanoparticle-Based Drug Delivery(44), Urinary and Genital Oncology Studies(44), Nanoplatforms for cancer theranostics(43)

Publications234 total

Figure S4 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S9 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S2 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S6 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S7 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S3 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Table S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
Figure S10 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
2025Open Access
FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
Supplementary Data Figures and Legends from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
Supplementary Tables S1-S3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
2025Open Access
page 1 of 12Next →

Frequent Co-authors

Jonathan Chou(15), Felix Y. Feng(14), Emily A. Egusa(12), Bradley A. Stohr(9), Eric J. Small(9), Michelle L. Badura(8), Kai Trepka(8), Emily Chan(8), Veronica Steri(7), Rahul Aggarwal(7), Anil P. Bidkar(6), Troy M. Robinson(6), Alan Ashworth(6), Robert R. Flavell(6), Farid Chehab(6), Wei Shuai(5), Sinan Wang(5), Fei Lee(5), Tanushree Shenoy(5), Jiaoti Huang(5)